Phase I clinical study of LBP KP01
Latest Information Update: 21 Nov 2020
At a glance
- Drugs LBP-KP01 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions
- 21 Nov 2020 New trial record
- 10 Nov 2020 According to a CARB-X media release, CARB-X is awarding up to US$2.05 million to Locus Biosciences to support preclinical development of LBP-KP01 and potential progression to Phase 1 development.